Resumen
Mujer de 35 años de edad que acude con un carcinoma lobulillar infiltrante de la mama. Fue tratada con mastectomía y disección axilar (T1N1Mx), cobalto-terapia y quimioterapia (CMF). Después de 6 años de remisión completa fue diagnosticada de metástasis suprarrenales aisladas tratadas con cirugía radical. Se comenta la relación entre el carcinoma de mama y las metástasis endocrinas, así como la relevancia de la detección immunohistoquímica de resistencia multi-farmacológica en el tratamiento.
References
Crown J. Evolution in the treatment of advanced breast cancer. Semin Oncol 1998;25 Suppl 12:12–7.
Bumpers HL, Hassett JM, Penetrante RB, Hoover EL, Holyoke ED. Endocrine organ metastases in subjects with lobular carcinoma of the breast. Arch Surg 1993; 128:1344–7.
Sastre-Garau X, Jouve M, Asselain B et al. Infiltrating lobular carcinoma of the breast. Cancer 1996;77:113–20.
Lamovec J, Bracko M. Metastasic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 1991;48:28–33.
Winchester DJ, Chang HL, Graves TA, Menck HR, Bland KI, Wichester DP. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg 1998;186: 416–22.
Toikkanen S, Pylkkänen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997; 76:1234–40.
Parham DM, Robertson AJ. A retrospective study of breast carcinoma: causes of death and pattern of metastases. Br J Cancer 1989; 60:394–6.
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1997; 235:177–82.
Gusterson BA, Gelber RD, Glodhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International Ludwig Breast Cancer Study Group. J Clin Oncol 1992;10: 1049–56.
Verrelle P, Meissonnier F, Ronck Y, et al. Clincial relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83:111–6.
Durphy FR, Spitzer G, Fornoff JER, et al. Factors predicting long-term survival for metastasic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994;73:2157–67.
Pacini P, Rinaldini M, Algeri R, et al. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanoed breast cancer. A multicentric randomised study. Final results. Eur J Cancer 2000;36: 966–75.
Frasci G, Comella P, D'Aiuto G. Weekly docetaxel plus gemcitabine or vinorebine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 2000;11:367–71.
Lo CY, van Heeden JA, Soreide JA, et al. Adrenalectomy for metastasic disease to the adrenal glands. Br J Surg 1996;83:528–31.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sebastian, A.A., Gómez, J.L., del Valle, A.T. et al. Adrenalectomy in an isolated adrenal gland metastasis of invasive lobular carcinoma. Rev Oncol 4, 43–45 (2002). https://doi.org/10.1007/BF02711639
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02711639